ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
- None.
- None.
Insights
The issuance of US Patent No. 11,878,038 to ELEVAI LABS, INC. represents a significant milestone in the company's intellectual property strategy. The patent protection on their exosome-based skin care formulations could potentially provide a competitive advantage in the medical aesthetics market. Exosomes are extracellular vesicles that are gaining attention in various therapeutic areas due to their role in cell communication. Their application in skin care is based on their potential to deliver active ingredients effectively and influence skin health at a cellular level.
For stakeholders, the short-term implications include potential market exclusivity for ELEVAI's enfinity™ and empower™ products, which can lead to increased sales and market share. In the long-term, a robust patent portfolio can deter competition and attract partnerships or licensing deals, contributing to sustained revenue growth. However, the actual market impact will depend on the efficacy of the products, market acceptance and the ability to defend the patent against infringement.
The medical aesthetics industry is highly competitive, with constant innovation and consumer demand for effective, non-invasive treatments. The patent grant not only solidifies ELEVAI's position but also could influence the broader industry trends towards biotechnological advancements in skin care. Market research indicates a growing consumer interest in scientifically-backed skin care solutions, which suggests a favorable reception for ELEVAI's exosome-based products.
Investors should monitor ELEVAI's market performance following this announcement, as well as any strategic moves by competitors in response. The company's ability to capitalize on this patent by scaling production and distribution will be critical in translating the patent win into tangible financial success.
The grant of a utility patent is a quantifiable asset that can enhance a company's valuation. ELEVAI's stock (NASDAQ: ELAB) may experience positive investor sentiment as patents often lead to a perception of reduced risk and potential for increased profits. However, investors should scrutinize ELEVAI's financials to evaluate the cost of patent maintenance, R&D expenses and the impact on profit margins.
It is also important to consider the company's strategy for monetizing the patent, such as through direct sales, partnerships, or licensing. The long-term financial health of ELEVAI will be influenced by the company's effectiveness in leveraging this patent to secure a dominant position in the physician-dispensed skincare market.
Utility Patent Covers the formulation for ELEVAI’s flagship exosome-based skin care products
NEWPORT BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, is pleased to announce today that the United States Patent & Trademark Office (USPTO) issued US Patent No. 11,878,038, entitled “Exosome-based Skincare Product” (the “Patent”) covering the primary formulation for ELEVAI’s exosome-based skin care products. The ELEVAI exosomes™ used in ELEVAI Labs’ formulations are derived from specially cultured and treated umbilical mesenchymal stem cells to generate a specific profile for the applications desired. ELEVAI’s enfinity™ and empower™ formulations are both covered by the Patent.
“We are pleased the USPTO has issued this critical patent, which is the first step towards building ELEVAI’s patent moat in the aesthetics market. The Company will continue to strive to invent or acquire the best and most technically advanced products, which we believe will maintain ELEVAI’s competitive edge in the physician-dispensed skincare market and beyond,” said ELEVAI co-founder and CEO, Jordan R. Plews, PhD.
About ELEVAI Labs
ELEVAI Labs, Inc. (NASDAQ: ELAB) is a medical aesthetics company developing cutting-edge physician-dispensed skin care applications. The company solves unmet needs in the medical aesthetics space through a combination of cutting-edge science-driven and next-generation consumer applications. ELEVAI Labs develops topical aesthetic skin care cosmetic products for the physician-dispensed market, with a focus on leveraging a proprietary stem cell exosome technology. For more information visit www.elevaiskincare.com.
Forward-Looking Statements
Certain statements made in this press release are "forward-looking statements'' within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified using words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected research & development and production targets; (ii) changes in applicable laws or regulations; and (iii) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC"). These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether because of new information, future developments, or otherwise, except as required by law.
Media Contact
Brenda Buechler
Chief Marketing Officer
contact@elevailabs.com
Investor Relations
IR@elevailabs.com
FAQ
What is the ticker symbol for ELEVAI LABS, INC.?
What is the title of the utility patent granted to ELEVAI LABS, INC.?
What products are covered by the utility patent granted to ELEVAI LABS, INC.?
What sets ELEVAI LABS, INC.'s exosome-based skincare products apart in the market?
Who is the co-founder and CEO of ELEVAI LABS, INC.?
